SlideShare a Scribd company logo
1 of 21
Download to read offline
Building Global Leadership in
Consumer Healthcare
June 27, 2016
2
Forward Looking Statements
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties,
many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or projected by, the forward-looking information
and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be
filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect
the availability or commercial potential of such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing
interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required
by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or
statements.
3
Agenda
3
Building Global Leadership in Consumer Healthcare
● Jérôme Contamine - Executive Vice President, Chief Financial Officer
● Vincent Warnery - Senior Vice President, Global Consumer Healthcare Business Unit
Q&A Session
RESHAPING THE PORTFOLIO
Jérôme Contamine
Executive Vice President, Chief Financial Officer
4
Asset Swap of Sanofi Animal Health Business and
Boehringer Ingelheim (BI) Consumer Healthcare Business
5
BI Consumer Healthcare €6.7bn
plus gross cash payment €4.7bn
Sanofi Animal Health €11.4bn
(1) Following consultations with the relevant social bodies and subject to appropriate regulatory approvals
(2) integration would start after closing. and will be dependent on market authorization transfers in each country
Enterprise Value
June 27, 2016
Signing of deal announced
Year-end 2016
Expected close of the transaction(1)
Progressive integration
Country-by-country basis(2)
Deal is Consistent with our Strategic Priority of
Reshaping the Portfolio Focused on Human Health
6
(1) Managed by Sanofi Genzyme Global Business Unit
(2) Managed by the General Medicines and Emerging Markets Global Business Unit
● Animal Health
● Generics(2)
in Europe
● Diabetes/
Cardiovascular
● Vaccines
● Rare Diseases(1)
● Emerging Markets(2)
Explore strategic
options
Sustain
leadership
Build competitive
positions
A B C
● Animal Health
● Consumer
Healthcare(2)
● Multiple Sclerosis(1)
● Oncology(1)
● Immunology(1)
Global Consumer Healthcare Market Offers Sustainable
Mid-Single Digit Growth
7
● Large global CHC market has delivered
consistent mid-single digit growth in
recent years
● Market growth of 5.5% in 2015
● Market growth expected to be 4.5%
(2015-2020 CAGR)(1)
● Consumer healthcare market driven by
GDP growth and demographics
● Increased health awareness and growing
propensity to self-medicate
● Brand equity offers more sustainable and
less volatile revenue streams
2015
€109bn
~4.5%
CAGR
(1) Nicholas Hall & Company, FY 2015
2010
BUILDING GLOBAL LEADERSHIP
IN CONSUMER HEALTHCARE
Vincent Warnery
Senior Vice President,
Global Consumer Healthcare Business Unit
8
1
2
3
Asset Swap is a Major Step Toward our Vision for CHC
9
Maximize Potential
of Existing Brands
Shape New
Categories
Pursue External
Growth Opportunities
● Consumer-driven
innovations
● Unique business model
● Geographic expansion
● Global & regional
OTC switch opportunities
● Leverage consumer
trends & preferences
● Reach critical scale in
key countries
● Optimize portfolio in
priority categories
CHC Vision
2020
9
12% 9%
6%
4%
3%
3%
3%
3%
3%
2%
52%
10
Sanofi has a Leading Portfolio of Consumer
Healthcare Brands
10
NO-SPA
2015 Global CHC Sales by Brand
Total: €3.35bn(1)
(1) Value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign exchange rates
(2) Vitamins, Minerals and Supplements
(3) Nicholas Hall & Company, FY 2015
Other
 Top-5 position in VMS(2), Digestive
Health, Pain Care, Allergy Solutions,
Feminine Care(3)
● Cough & Cold: strategic interest to
balance seasonal allergy category
 Global footprint
● 46.5% of CHC sales were generated
in Emerging Markets in 2015(1)
● #1 in France and Australia(3)
 10 key Sanofi brands
● ~50% of Sanofi CHC sales in 2015
14%
14%
11%
9%
7%
4%
41%
11
Gaining Category and Regional Leadership with
Iconic Boehringer Ingelheim Brands
11
 6 key BI brands
● ~60% of sales in 2015
 Strengths in Digestive Health and
Cough & Cold categories
● #6 in Digestive Health(2)
● #7 in Cough & Cold(2)
 Largest countries by net sales:
Japan (€299m), U.S. (€186m) and
Germany (€162m)
(1) Transaction perimeter excludes CHC in China; value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign
exchange rates
(2) Nicholas Hall & Company, FY 2015
Other
2015 Global CHC Sales by Brand
Total: €1.53bn(1)
4.5%
4.4%
4.3%
4.2%
3.5%
2.5%
2.0%
1.4%
1.0%
A Strong Strategic Rationale for Our Ambitions in
Consumer Healthcare
12
Other
Taisho
Reckitt Benckiser
Pfizer
J&J
GSK
Takeda
P&G
Bayer +
(1) Nicholas Hall & Company, FY 2015
(2) Excludes BI CHC in China
● Market share of 4.3% in 2015(1,2)
● Leverage scale in a fragmented market
● Opportunity for strategic consolidation
● Expand global footprint
● Brand equity offers more sustainable
revenue streams
● No patent cliff
● ‘Ever-lasting’ brands
Sanofi to Become a Leading Player in the €109bn OTC Market(1)
Combined Sanofi and BI OTC Businesses Have
Outgrown the Market in Recent Years
13
A top combined growth profile among leading players
Combined 2010-2015 OTC Sales
(1)
(€m)
2010 2015
+5.8%
70%
30%
67%
33%
2010-2015 CAGR
(1)
P&G
J&J
Taisho
Bayer
Takeda
Pfizer
Reckitt Benckiser 5.7%
OTC Market Growth: 4.4%
5.8%
5.3%
4.5%
3.8%
3.1%
0.3%
-2.1%
1.9%GSK
+
(1) Nicholas Hall & Company, FY 2015; Organic growth at CER; Excludes BI CHC in China
BI Brands Complementary in Four Priority Categories
14
Segment Size(1)
in €bn
32.1 #5 #3
18.9 #11 #6
15.5 #5 #1
14.6 #4 #2
3.7 #3 #3
0.9 #1 #1
+
Sanofi
Global Categories
Market Rank(1,2)
(1) Nicholas Hall & Company, FY 2015
(2) Excludes BI CHC in China
€1bn
€1.4bn
€0.9bn
€0.6bn
€0.7bn
EUROPE
#4#1
ASIA-JPAC
#8#2
ROW(2)
#2LATAM
#1
N. AMERICA
(1) Nicholas Hall & Company, FY 2015; Excludes BI CHC in China
(2) CIS, Middle-East Africa and South Asia
(3) Including Digestive Health and Cough & Cold categories
Asset Swap Expands Sanofi’s CHC Scale in Europe
and JPAC Regions(1)
15
Germany will be a key center of Sanofi’s CHC business(3)
#7#6
CLOSING REMARKS
Jérôme Contamine
Executive Vice President, Chief Financial Officer
16
A Value Creating Transaction Based on Strong Financials
Expected
Transaction
Benefits
● Increased scale in Consumer Healthcare business
● Combined CHC global sales of approximately €4.9bn in 2015(1)
● Value creation
● Synergies in advertising and promotional activities
(e.g. Sanofi medical sales force to support BI brands, pipeline, etc.)
● Stronger global commercial platform for potential OTC launches and Rx switches
● Financial implications
● BOI margin contribution of the CHC business expected to be around 30% in 2018
● Continue to expect transaction to be business EPS neutral in 2017 and accretive in
subsequent years
(1) Excludes Boehringer Ingelheim CHC in China; value of CHC sales in Venezuela have been reduced to
nearly zero due to revision of foreign exchange rates by both companies 17
18
Asset Swap Achieves Key Strategic Goal of Becoming a
Leader in Consumer Healthcare
● Global CHC market offers sustainable mid-single digit growth(1)
● Complementary portfolio increases market position
in priority categories and scale in some major countries
● Global integration to begin upon the expected completion
of the transaction by year-end 2016
● New CHC Global Business Unit will be formed
● Supports vision of a diversified global healthcare company
focused on human health
1
2
4
3
(1) Nicholas Hall & Company, FY 2015
19
Q&A SESSION
20
APPENDIX
Combined Sales in Key Categories in 2015 (in €m)
Combined Sales in Key Geographies in 2015 (in €m)
€787m €845m €550m €432m €730m
€454m €364m €411m €241m €61m
€551m
€848m
€196m €223m €427m €134m
€927m €466m €476m €628m
Other(2)
€791m€673m
BI Brands Add Significantly to Sanofi’s Presence in
Key CHC Categories & Geographies(1)
€961m€1,209m
€762m
MEA/CIS/
South Asia
€902m
Asia
Pacific
€690m
Latin
America
€1,123m
North
America
€1,399m
Europe
MEA: Middle East Africa CIS: Commonwealth of Independent States
(1) Sanofi CHC published and Boehringer Ingelheim 2015 sales at published rates; Excludes Boehringer Ingelheim CHC in China;
value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign exchange rates by both companies
(2) Others: Feminine Care, Lifestyle OTS’s, etc.
21
€1,241m

More Related Content

What's hot

Boehringer Ingelheim Introduction - Prepared by Deep Shah
Boehringer Ingelheim Introduction - Prepared by Deep ShahBoehringer Ingelheim Introduction - Prepared by Deep Shah
Boehringer Ingelheim Introduction - Prepared by Deep ShahAkshay Saxena
 
How to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanHow to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanMuhammad Ali Jehangir
 
Gsk pakistan limited final presentation
Gsk pakistan limited final presentation Gsk pakistan limited final presentation
Gsk pakistan limited final presentation Muhammad Rafay
 
Teva pharmaceutical industries limited
Teva pharmaceutical industries limitedTeva pharmaceutical industries limited
Teva pharmaceutical industries limitedadgjll
 
Colgate-Palmolive Company Case Analysis
Colgate-Palmolive Company Case AnalysisColgate-Palmolive Company Case Analysis
Colgate-Palmolive Company Case AnalysisArnav Das
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryYee Jie NG
 
Case study of Arla Foods by Ewelina Brania
Case study of Arla Foods by Ewelina BraniaCase study of Arla Foods by Ewelina Brania
Case study of Arla Foods by Ewelina BraniaEwelina
 
Proctor And Gamble
Proctor And GambleProctor And Gamble
Proctor And Gamblefjpaul1
 
Case Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineCase Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineAanchal Saxena
 
Teva Pharmaceuticals
Teva PharmaceuticalsTeva Pharmaceuticals
Teva PharmaceuticalsCJ_Wei
 
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLERBiocat, BioRegion of Catalonia
 
Haier: Taking a chinese company global in 2011
Haier: Taking a chinese company global in 2011Haier: Taking a chinese company global in 2011
Haier: Taking a chinese company global in 2011Ilaria Fiore
 
Presentation CISCO & HP
Presentation CISCO & HPPresentation CISCO & HP
Presentation CISCO & HPAbhijat Dhawal
 
Parkville strategic project final-converted
Parkville   strategic project final-convertedParkville   strategic project final-converted
Parkville strategic project final-convertedMohamed Ahmed
 
Glaxo smith-kline-presentation
Glaxo smith-kline-presentationGlaxo smith-kline-presentation
Glaxo smith-kline-presentationHarram Aneeqa
 

What's hot (20)

Boehringer Ingelheim Introduction - Prepared by Deep Shah
Boehringer Ingelheim Introduction - Prepared by Deep ShahBoehringer Ingelheim Introduction - Prepared by Deep Shah
Boehringer Ingelheim Introduction - Prepared by Deep Shah
 
How to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanHow to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing Plan
 
Gsk pakistan limited final presentation
Gsk pakistan limited final presentation Gsk pakistan limited final presentation
Gsk pakistan limited final presentation
 
Beximco pharma
Beximco pharmaBeximco pharma
Beximco pharma
 
Teva pharmaceutical industries limited
Teva pharmaceutical industries limitedTeva pharmaceutical industries limited
Teva pharmaceutical industries limited
 
Colgate-Palmolive Company Case Analysis
Colgate-Palmolive Company Case AnalysisColgate-Palmolive Company Case Analysis
Colgate-Palmolive Company Case Analysis
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical Industry
 
Case study of Arla Foods by Ewelina Brania
Case study of Arla Foods by Ewelina BraniaCase study of Arla Foods by Ewelina Brania
Case study of Arla Foods by Ewelina Brania
 
Proctor And Gamble
Proctor And GambleProctor And Gamble
Proctor And Gamble
 
Lego Outsourcing
Lego OutsourcingLego Outsourcing
Lego Outsourcing
 
Case Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineCase Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithkline
 
Glaxo smith kline
Glaxo smith klineGlaxo smith kline
Glaxo smith kline
 
Teva Pharmaceuticals
Teva PharmaceuticalsTeva Pharmaceuticals
Teva Pharmaceuticals
 
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
 
Haier: Taking a chinese company global in 2011
Haier: Taking a chinese company global in 2011Haier: Taking a chinese company global in 2011
Haier: Taking a chinese company global in 2011
 
Sanofi
SanofiSanofi
Sanofi
 
Presentation CISCO & HP
Presentation CISCO & HPPresentation CISCO & HP
Presentation CISCO & HP
 
Parkville strategic project final-converted
Parkville   strategic project final-convertedParkville   strategic project final-converted
Parkville strategic project final-converted
 
Glaxo smith-kline-presentation
Glaxo smith-kline-presentationGlaxo smith-kline-presentation
Glaxo smith-kline-presentation
 
Gillete final report
Gillete final reportGillete final report
Gillete final report
 

Viewers also liked

2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab2016/10 – IR call – Dupilumab
2016/10 – IR call – DupilumabSanofi
 
2015/11 - IR - Sarilumab
2015/11 - IR - Sarilumab2015/11 - IR - Sarilumab
2015/11 - IR - SarilumabSanofi
 
2015/03 - IR - Diabetes
2015/03 - IR - Diabetes2015/03 - IR - Diabetes
2015/03 - IR - DiabetesSanofi
 
2015/07 – IR – Praluent
2015/07 – IR – Praluent2015/07 – IR – Praluent
2015/07 – IR – PraluentSanofi
 
2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi ManagementSanofi
 
Annual Results 2016
Annual Results 2016Annual Results 2016
Annual Results 2016Sanofi
 
2017/03 – IR call - Dupixent®
2017/03 – IR call - Dupixent®2017/03 – IR call - Dupixent®
2017/03 – IR call - Dupixent®Sanofi
 
Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi Sanofi
 
General Meeting 2016
General Meeting 2016General Meeting 2016
General Meeting 2016Sanofi
 
State of the Consumer Health Industry in 2014
State of the Consumer Health Industry in 2014State of the Consumer Health Industry in 2014
State of the Consumer Health Industry in 2014Euromonitor International
 
2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS Health2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS HealthQuintilesIMS Asia Pacific
 
Q2 2016 Results by Sanofi
Q2 2016 Results by SanofiQ2 2016 Results by Sanofi
Q2 2016 Results by SanofiSanofi
 
Market Oveview: Identifying New Trends and Opportunities in the Global Infant...
Market Oveview: Identifying New Trends and Opportunities in the Global Infant...Market Oveview: Identifying New Trends and Opportunities in the Global Infant...
Market Oveview: Identifying New Trends and Opportunities in the Global Infant...Euromonitor International
 
Atopic dermatitis by Dr.Gamal Soltan
Atopic dermatitis by Dr.Gamal SoltanAtopic dermatitis by Dr.Gamal Soltan
Atopic dermatitis by Dr.Gamal Soltangamal sultan
 
Strategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisStrategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisBruno Rakotozafy
 
Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...
Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...
Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...Euromonitor International
 

Viewers also liked (19)

2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab
 
2015/11 - IR - Sarilumab
2015/11 - IR - Sarilumab2015/11 - IR - Sarilumab
2015/11 - IR - Sarilumab
 
2015/03 - IR - Diabetes
2015/03 - IR - Diabetes2015/03 - IR - Diabetes
2015/03 - IR - Diabetes
 
2015/07 – IR – Praluent
2015/07 – IR – Praluent2015/07 – IR – Praluent
2015/07 – IR – Praluent
 
2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management
 
Annual Results 2016
Annual Results 2016Annual Results 2016
Annual Results 2016
 
2017/03 – IR call - Dupixent®
2017/03 – IR call - Dupixent®2017/03 – IR call - Dupixent®
2017/03 – IR call - Dupixent®
 
Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi
 
Atopic dermatitis update
Atopic dermatitis  updateAtopic dermatitis  update
Atopic dermatitis update
 
General Meeting 2016
General Meeting 2016General Meeting 2016
General Meeting 2016
 
State of the Consumer Health Industry in 2014
State of the Consumer Health Industry in 2014State of the Consumer Health Industry in 2014
State of the Consumer Health Industry in 2014
 
2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS Health2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS Health
 
Q2 2016 Results by Sanofi
Q2 2016 Results by SanofiQ2 2016 Results by Sanofi
Q2 2016 Results by Sanofi
 
Market Oveview: Identifying New Trends and Opportunities in the Global Infant...
Market Oveview: Identifying New Trends and Opportunities in the Global Infant...Market Oveview: Identifying New Trends and Opportunities in the Global Infant...
Market Oveview: Identifying New Trends and Opportunities in the Global Infant...
 
Global OTC Market
Global OTC MarketGlobal OTC Market
Global OTC Market
 
Atopic dermatitis by Dr.Gamal Soltan
Atopic dermatitis by Dr.Gamal SoltanAtopic dermatitis by Dr.Gamal Soltan
Atopic dermatitis by Dr.Gamal Soltan
 
Strategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisStrategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi Aventis
 
Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...
Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...
Global State of the Industry: A Review of the Top Tea Trends and Markets Arou...
 
reveal.js 3.0.0
reveal.js 3.0.0reveal.js 3.0.0
reveal.js 3.0.0
 

Similar to 2016/06 – IR – Business swap with Boehringer Ingelheim

2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC ConferenceSanofi
 
2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC ConferenceSanofi
 
Q1 2017 Results by Sanofi
Q1 2017 Results by SanofiQ1 2017 Results by Sanofi
Q1 2017 Results by SanofiSanofi
 
Q3 2017 Results
Q3 2017 Results Q3 2017 Results
Q3 2017 Results Sanofi
 
Q2 2017 Results by Sanofi
Q2 2017 Results by SanofiQ2 2017 Results by Sanofi
Q2 2017 Results by SanofiSanofi
 
Q4 and FY 2017 Results
Q4 and FY 2017 ResultsQ4 and FY 2017 Results
Q4 and FY 2017 ResultsSanofi
 
Q3 2019 Results
Q3 2019 ResultsQ3 2019 Results
Q3 2019 ResultsSanofi
 
Annual Results 2015
Annual Results 2015Annual Results 2015
Annual Results 2015Sanofi
 
Q4 and Full Year 2019 Results
Q4 and Full Year 2019 ResultsQ4 and Full Year 2019 Results
Q4 and Full Year 2019 ResultsSanofi
 
Q2 2019 Results
Q2 2019 ResultsQ2 2019 Results
Q2 2019 ResultsSanofi
 
Q2 2014 Results by Sanofi
Q2 2014 Results by SanofiQ2 2014 Results by Sanofi
Q2 2014 Results by SanofiSanofi
 
Q3 2020 Results
Q3 2020 ResultsQ3 2020 Results
Q3 2020 ResultsSanofi
 
Q1 2019 Results
Q1 2019 ResultsQ1 2019 Results
Q1 2019 ResultsSanofi
 
Annual Results 2014
Annual Results 2014Annual Results 2014
Annual Results 2014Sanofi
 
Third quarter 2023 Results
Third quarter 2023 ResultsThird quarter 2023 Results
Third quarter 2023 ResultsSanofi
 
Q1 2018 Results
Q1 2018 ResultsQ1 2018 Results
Q1 2018 ResultsSanofi
 
Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi Sanofi
 
GNC Presentation on Growth from 2011
GNC Presentation on Growth from 2011GNC Presentation on Growth from 2011
GNC Presentation on Growth from 2011Neil Kimberley
 
Q1 2016 Results by Sanofi
Q1 2016 Results by SanofiQ1 2016 Results by Sanofi
Q1 2016 Results by SanofiSanofi
 

Similar to 2016/06 – IR – Business swap with Boehringer Ingelheim (20)

2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference
 
2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference
 
Q1 2017 Results by Sanofi
Q1 2017 Results by SanofiQ1 2017 Results by Sanofi
Q1 2017 Results by Sanofi
 
Q3 2017 Results
Q3 2017 Results Q3 2017 Results
Q3 2017 Results
 
Q2 2017 Results by Sanofi
Q2 2017 Results by SanofiQ2 2017 Results by Sanofi
Q2 2017 Results by Sanofi
 
Q4 and FY 2017 Results
Q4 and FY 2017 ResultsQ4 and FY 2017 Results
Q4 and FY 2017 Results
 
Q3 2019 Results
Q3 2019 ResultsQ3 2019 Results
Q3 2019 Results
 
Annual Results 2015
Annual Results 2015Annual Results 2015
Annual Results 2015
 
Q4 and Full Year 2019 Results
Q4 and Full Year 2019 ResultsQ4 and Full Year 2019 Results
Q4 and Full Year 2019 Results
 
Q2 2019 Results
Q2 2019 ResultsQ2 2019 Results
Q2 2019 Results
 
Q2 2014 Results by Sanofi
Q2 2014 Results by SanofiQ2 2014 Results by Sanofi
Q2 2014 Results by Sanofi
 
Q3 2020 Results
Q3 2020 ResultsQ3 2020 Results
Q3 2020 Results
 
Q1 2019 Results
Q1 2019 ResultsQ1 2019 Results
Q1 2019 Results
 
Annual Results 2014
Annual Results 2014Annual Results 2014
Annual Results 2014
 
Third quarter 2023 Results
Third quarter 2023 ResultsThird quarter 2023 Results
Third quarter 2023 Results
 
Q1 2018 Results
Q1 2018 ResultsQ1 2018 Results
Q1 2018 Results
 
Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi
 
GNC Presentation on Growth from 2011
GNC Presentation on Growth from 2011GNC Presentation on Growth from 2011
GNC Presentation on Growth from 2011
 
Valeant Investor Day 2015 Presentation
Valeant Investor Day 2015 PresentationValeant Investor Day 2015 Presentation
Valeant Investor Day 2015 Presentation
 
Q1 2016 Results by Sanofi
Q1 2016 Results by SanofiQ1 2016 Results by Sanofi
Q1 2016 Results by Sanofi
 

More from Sanofi

Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsFourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsSanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlightsSanofi
 
First quarter 2023 results
First quarter 2023 resultsFirst quarter 2023 results
First quarter 2023 resultsSanofi
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlightsSanofi
 
Sanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi
 
2022 full-year results highlights
2022 full-year results highlights2022 full-year results highlights
2022 full-year results highlightsSanofi
 
L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 Sanofi
 
Presentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsPresentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsSanofi
 
Q3 2022 Results
Q3 2022 ResultsQ3 2022 Results
Q3 2022 ResultsSanofi
 
Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Sanofi
 
Second quarter 2022 results
Second quarter 2022 results Second quarter 2022 results
Second quarter 2022 results Sanofi
 
Q1 First quarter results
Q1 First quarter resultsQ1 First quarter results
Q1 First quarter resultsSanofi
 
Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Sanofi
 
First quarter 2022 results
First quarter 2022 resultsFirst quarter 2022 results
First quarter 2022 resultsSanofi
 
Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Sanofi
 
Sanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial ResultsSanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial ResultsSanofi
 
Presentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovationPresentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovationSanofi
 

More from Sanofi (20)

Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsFourth quarter and full year 2023 results
Fourth quarter and full year 2023 results
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlights
 
First quarter 2023 results
First quarter 2023 resultsFirst quarter 2023 results
First quarter 2023 results
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlights
 
Sanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 results
 
2022 full-year results highlights
2022 full-year results highlights2022 full-year results highlights
2022 full-year results highlights
 
L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022
 
Presentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsPresentation of the Q3 2022 Results
Presentation of the Q3 2022 Results
 
Q3 2022 Results
Q3 2022 ResultsQ3 2022 Results
Q3 2022 Results
 
Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022
 
Second quarter 2022 results
Second quarter 2022 results Second quarter 2022 results
Second quarter 2022 results
 
Q1 First quarter results
Q1 First quarter resultsQ1 First quarter results
Q1 First quarter results
 
Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Résultats du premier trimestre 2022
Résultats du premier trimestre 2022
 
First quarter 2022 results
First quarter 2022 resultsFirst quarter 2022 results
First quarter 2022 results
 
Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Q4 and Full Year Results 2021
Q4 and Full Year Results 2021
 
Sanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial ResultsSanofi Q4 2021 Final Financial Results
Sanofi Q4 2021 Final Financial Results
 
Presentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovationPresentation Part 2 – Leading with innovation
Presentation Part 2 – Leading with innovation
 

Recently uploaded

Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...narwatsonia7
 
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...narwatsonia7
 
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment BookingCall Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Bookingnarwatsonia7
 
Call Girls Viman Nagar 7001305949 All Area Service COD available Any Time
Call Girls Viman Nagar 7001305949 All Area Service COD available Any TimeCall Girls Viman Nagar 7001305949 All Area Service COD available Any Time
Call Girls Viman Nagar 7001305949 All Area Service COD available Any Timevijaych2041
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...narwatsonia7
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...rajnisinghkjn
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbersBook Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbersnarwatsonia7
 
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...narwatsonia7
 
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls ServiceCall Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Servicesonalikaur4
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking ModelsMumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Modelssonalikaur4
 
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...narwatsonia7
 

Recently uploaded (20)

Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
 
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
 
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment BookingCall Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
 
Call Girls Viman Nagar 7001305949 All Area Service COD available Any Time
Call Girls Viman Nagar 7001305949 All Area Service COD available Any TimeCall Girls Viman Nagar 7001305949 All Area Service COD available Any Time
Call Girls Viman Nagar 7001305949 All Area Service COD available Any Time
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Dwarka Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbersBook Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
 
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
 
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls ServiceCall Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking ModelsMumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
 
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
 

2016/06 – IR – Business swap with Boehringer Ingelheim

  • 1. Building Global Leadership in Consumer Healthcare June 27, 2016
  • 2. 2 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • 3. 3 Agenda 3 Building Global Leadership in Consumer Healthcare ● Jérôme Contamine - Executive Vice President, Chief Financial Officer ● Vincent Warnery - Senior Vice President, Global Consumer Healthcare Business Unit Q&A Session
  • 4. RESHAPING THE PORTFOLIO Jérôme Contamine Executive Vice President, Chief Financial Officer 4
  • 5. Asset Swap of Sanofi Animal Health Business and Boehringer Ingelheim (BI) Consumer Healthcare Business 5 BI Consumer Healthcare €6.7bn plus gross cash payment €4.7bn Sanofi Animal Health €11.4bn (1) Following consultations with the relevant social bodies and subject to appropriate regulatory approvals (2) integration would start after closing. and will be dependent on market authorization transfers in each country Enterprise Value June 27, 2016 Signing of deal announced Year-end 2016 Expected close of the transaction(1) Progressive integration Country-by-country basis(2)
  • 6. Deal is Consistent with our Strategic Priority of Reshaping the Portfolio Focused on Human Health 6 (1) Managed by Sanofi Genzyme Global Business Unit (2) Managed by the General Medicines and Emerging Markets Global Business Unit ● Animal Health ● Generics(2) in Europe ● Diabetes/ Cardiovascular ● Vaccines ● Rare Diseases(1) ● Emerging Markets(2) Explore strategic options Sustain leadership Build competitive positions A B C ● Animal Health ● Consumer Healthcare(2) ● Multiple Sclerosis(1) ● Oncology(1) ● Immunology(1)
  • 7. Global Consumer Healthcare Market Offers Sustainable Mid-Single Digit Growth 7 ● Large global CHC market has delivered consistent mid-single digit growth in recent years ● Market growth of 5.5% in 2015 ● Market growth expected to be 4.5% (2015-2020 CAGR)(1) ● Consumer healthcare market driven by GDP growth and demographics ● Increased health awareness and growing propensity to self-medicate ● Brand equity offers more sustainable and less volatile revenue streams 2015 €109bn ~4.5% CAGR (1) Nicholas Hall & Company, FY 2015 2010
  • 8. BUILDING GLOBAL LEADERSHIP IN CONSUMER HEALTHCARE Vincent Warnery Senior Vice President, Global Consumer Healthcare Business Unit 8
  • 9. 1 2 3 Asset Swap is a Major Step Toward our Vision for CHC 9 Maximize Potential of Existing Brands Shape New Categories Pursue External Growth Opportunities ● Consumer-driven innovations ● Unique business model ● Geographic expansion ● Global & regional OTC switch opportunities ● Leverage consumer trends & preferences ● Reach critical scale in key countries ● Optimize portfolio in priority categories CHC Vision 2020 9
  • 10. 12% 9% 6% 4% 3% 3% 3% 3% 3% 2% 52% 10 Sanofi has a Leading Portfolio of Consumer Healthcare Brands 10 NO-SPA 2015 Global CHC Sales by Brand Total: €3.35bn(1) (1) Value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign exchange rates (2) Vitamins, Minerals and Supplements (3) Nicholas Hall & Company, FY 2015 Other  Top-5 position in VMS(2), Digestive Health, Pain Care, Allergy Solutions, Feminine Care(3) ● Cough & Cold: strategic interest to balance seasonal allergy category  Global footprint ● 46.5% of CHC sales were generated in Emerging Markets in 2015(1) ● #1 in France and Australia(3)  10 key Sanofi brands ● ~50% of Sanofi CHC sales in 2015
  • 11. 14% 14% 11% 9% 7% 4% 41% 11 Gaining Category and Regional Leadership with Iconic Boehringer Ingelheim Brands 11  6 key BI brands ● ~60% of sales in 2015  Strengths in Digestive Health and Cough & Cold categories ● #6 in Digestive Health(2) ● #7 in Cough & Cold(2)  Largest countries by net sales: Japan (€299m), U.S. (€186m) and Germany (€162m) (1) Transaction perimeter excludes CHC in China; value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign exchange rates (2) Nicholas Hall & Company, FY 2015 Other 2015 Global CHC Sales by Brand Total: €1.53bn(1)
  • 12. 4.5% 4.4% 4.3% 4.2% 3.5% 2.5% 2.0% 1.4% 1.0% A Strong Strategic Rationale for Our Ambitions in Consumer Healthcare 12 Other Taisho Reckitt Benckiser Pfizer J&J GSK Takeda P&G Bayer + (1) Nicholas Hall & Company, FY 2015 (2) Excludes BI CHC in China ● Market share of 4.3% in 2015(1,2) ● Leverage scale in a fragmented market ● Opportunity for strategic consolidation ● Expand global footprint ● Brand equity offers more sustainable revenue streams ● No patent cliff ● ‘Ever-lasting’ brands Sanofi to Become a Leading Player in the €109bn OTC Market(1)
  • 13. Combined Sanofi and BI OTC Businesses Have Outgrown the Market in Recent Years 13 A top combined growth profile among leading players Combined 2010-2015 OTC Sales (1) (€m) 2010 2015 +5.8% 70% 30% 67% 33% 2010-2015 CAGR (1) P&G J&J Taisho Bayer Takeda Pfizer Reckitt Benckiser 5.7% OTC Market Growth: 4.4% 5.8% 5.3% 4.5% 3.8% 3.1% 0.3% -2.1% 1.9%GSK + (1) Nicholas Hall & Company, FY 2015; Organic growth at CER; Excludes BI CHC in China
  • 14. BI Brands Complementary in Four Priority Categories 14 Segment Size(1) in €bn 32.1 #5 #3 18.9 #11 #6 15.5 #5 #1 14.6 #4 #2 3.7 #3 #3 0.9 #1 #1 + Sanofi Global Categories Market Rank(1,2) (1) Nicholas Hall & Company, FY 2015 (2) Excludes BI CHC in China
  • 15. €1bn €1.4bn €0.9bn €0.6bn €0.7bn EUROPE #4#1 ASIA-JPAC #8#2 ROW(2) #2LATAM #1 N. AMERICA (1) Nicholas Hall & Company, FY 2015; Excludes BI CHC in China (2) CIS, Middle-East Africa and South Asia (3) Including Digestive Health and Cough & Cold categories Asset Swap Expands Sanofi’s CHC Scale in Europe and JPAC Regions(1) 15 Germany will be a key center of Sanofi’s CHC business(3) #7#6
  • 16. CLOSING REMARKS Jérôme Contamine Executive Vice President, Chief Financial Officer 16
  • 17. A Value Creating Transaction Based on Strong Financials Expected Transaction Benefits ● Increased scale in Consumer Healthcare business ● Combined CHC global sales of approximately €4.9bn in 2015(1) ● Value creation ● Synergies in advertising and promotional activities (e.g. Sanofi medical sales force to support BI brands, pipeline, etc.) ● Stronger global commercial platform for potential OTC launches and Rx switches ● Financial implications ● BOI margin contribution of the CHC business expected to be around 30% in 2018 ● Continue to expect transaction to be business EPS neutral in 2017 and accretive in subsequent years (1) Excludes Boehringer Ingelheim CHC in China; value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign exchange rates by both companies 17
  • 18. 18 Asset Swap Achieves Key Strategic Goal of Becoming a Leader in Consumer Healthcare ● Global CHC market offers sustainable mid-single digit growth(1) ● Complementary portfolio increases market position in priority categories and scale in some major countries ● Global integration to begin upon the expected completion of the transaction by year-end 2016 ● New CHC Global Business Unit will be formed ● Supports vision of a diversified global healthcare company focused on human health 1 2 4 3 (1) Nicholas Hall & Company, FY 2015
  • 21. Combined Sales in Key Categories in 2015 (in €m) Combined Sales in Key Geographies in 2015 (in €m) €787m €845m €550m €432m €730m €454m €364m €411m €241m €61m €551m €848m €196m €223m €427m €134m €927m €466m €476m €628m Other(2) €791m€673m BI Brands Add Significantly to Sanofi’s Presence in Key CHC Categories & Geographies(1) €961m€1,209m €762m MEA/CIS/ South Asia €902m Asia Pacific €690m Latin America €1,123m North America €1,399m Europe MEA: Middle East Africa CIS: Commonwealth of Independent States (1) Sanofi CHC published and Boehringer Ingelheim 2015 sales at published rates; Excludes Boehringer Ingelheim CHC in China; value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign exchange rates by both companies (2) Others: Feminine Care, Lifestyle OTS’s, etc. 21 €1,241m